secwatch.observer — SEC 8-K summary
======================================

Issuer:     Spero Therapeutics, Inc. (SPRO)
CIK:        0001701108
Form:       8-K
Filed at:   2022-09-22T23:59:59+00:00
Accession:  0001193125-22-248772
Event type: m_and_a
Sentiment:  positive
Materiality: 0.85
Item codes: 1.01, 3.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Spero licenses tebipenem HBr to GSK for $66M upfront, up to $525M milestones plus tiered royalties
--------------------------------------------------------------------------------

- GSK gets exclusive license to develop and commercialize oral carbapenem antibiotic tebipenem HBr outside Japan and certain Asian countries.
- Spero receives $66M upfront; potential milestones: $150M Phase III delivery, $150M first sale (US/EU), $225M sales milestones up to $1B+.
- Tiered royalties low-single to low-double digit increase if net sales exceed $1B.
- GSK invests $9M in Spero common stock at ~$1.20805/share (7.45M shares), with lock-up and standstill provisions.
- Spero to start a new Phase 3 trial in 2023; closing expected Q4 2022 subject to HSR clearance.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1701108/000119312522248772/0001193125-22-248772-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1701108/000119312522248772/d370224d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-248772

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer